Arundhati Parmar is VP and Editor-in-Chief at MedCity News. In this role, she oversees MedCity's news coverage as well as develops the content for several conferences that the publication hosts. Previously, she was Senior Editor at UBM's Medical Device + Diagnostic Industry. Arundhati has three degrees from three continents - a Bachelor of Arts in English from Jadavpur University, Kolkata, India; a Masters in English Literature from the University of Sydney, Australia and a Masters in Journalism from Northwestern University in Chicago. She has sworn never to enter a classroom again. Contact her at [email protected].
LinkedIn: https://www.linkedin.com/in/arundhati-parmar/
Twitter: @aparmarbb
Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea. Lilly is now preparing regulatory submissions to add this indication to the drug’s label.
In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities.
The challenge? Maintaining high Star Ratings or improving upon existing ratings gets increasingly difficult over time.
AHIP, the AMA and NAACOS released a playbook last week that provides the best practices for value-based care. It is based on experiences from physicians, value-based care entities and payers.
Two Chairs, a startup offering hybrid behavioral health care, closed a $72 million Series C funding round. The company’s focus on measuring outcomes and dedication to care quality assurance are two key factors that differentiate it from other mental health startups, CEO Alex Katz said.
In vulnerable moments when employees need it most, virtual specialty care delivers a human connection that offers empathy, support, and guidance.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Intra-Cellular Therapies reported its drug Caplyta met the main and secondary goals in the first of three pivotal studies in major depressive disorder. Success in two of them could support expanding the label of the drug, which is currently approved in schizophrenia and bipolar depression.
Former U.S. CTO Aneesh Chopra will moderate a webinar on April 16 at 1pm ET on eConsent and interoperability with DocuSign, Velatura, Mid-State Health Network and Southwest Michigan Behavioral Health.
Two CVS stores in Rhode Island have filed petitions to join the Pharmacy Guild, which is building a national pharmacy union. The locations are close to CVS Health's headquarters in Woonsocket, Rhode Island.
Banner Health is deploying Qventus’ perioperative technology across the entire organization following the success of an initial pilot. The software integrates with EHRs and uses machine learning to automate operating room scheduling processes and maximize surgical caseloads.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Current technology can't single-handedly solve all dental workforce issues, but there is much it can do to lighten the burden.
The FDA clinical hold keeps Neumora Therapeutics from catching up to the field of biopharmaceutical companies pursuing the same target for schizophrenia. But Neumora remains on track with its lead program, a different drug in late-stage clinical testing for major depressive disorder.
Through a new partnership, health plans that use NationsBenefits can offer Instacart’s grocery delivery services as a supplemental benefit.
Atlantic Health System announced that it is adopting FeelBetter’s technology for polypharmacy patient management. The health system is now using the startup’s personalized medication management platform across its three ACOs.
Pharmaceutical companies use Feel Therapeutics’ technology to monitor the mental state of participants in clinical trials of behavioral medications. But the startup envisions its technology eventually also finding a place as a part of clinical care.
